ArticleExploration of targeted anti-tumor therapy2022

N6-methyladenosine-related microRNAs risk model trumps the isocitrate dehydrogenase mutation status as a predictive biomarker for the prognosis and immunotherapy in lower grade gliomas.

Feng Yuan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.